PMID- 36816840
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230224
IS  - 2405-6308 (Electronic)
IS  - 2405-6308 (Linking)
VI  - 39
DP  - 2023 Mar
TI  - Is single fraction the future of stereotactic body radiation therapy (SBRT)? A 
      critical appraisal of the current literature.
PG  - 100584
LID - 10.1016/j.ctro.2023.100584 [doi]
LID - 100584
AB  - Stereotactic Body Radiation Therapy (SBRT) is a standard of care for many 
      localizations but the question of the optimal fractionation remains a matter of 
      concern. If single fraction sessions are routinely used for intracranial targets, 
      their utilization for mobile extracranial lesions is a source of debate and 
      apprehension. Single session treatments improve patient comfort, provide a 
      medico-economic benefit, and have proven useful in the context of the SARS-CoV 2 
      pandemic. However, both technical and radiobiological uncertainties remain. 
      Experience from intracranial radiosurgery has shown that the size of the target, 
      its proximity to organs at risk, tumor histology, and the volume of normal tissue 
      irradiated are all determining factors in the choice of fractionation. The 
      literature on the use of single fraction for extracranial sites is still scarce. 
      Only primary and secondary pulmonary tumors have been evaluated in prospective 
      randomized trials, allowing the integration of these fractionation schemes in 
      daily practice, for highly selected cases and in trained teams. The level of 
      evidence for the other organs is mainly based on dose escalation or retrospective 
      trials and calls for caution, with further studies being needed before routine 
      use in clinical practice.
CI  - (c) 2023 Published by Elsevier B.V. on behalf of European Society for Radiotherapy 
      and Oncology.
FAU - Terlizzi, M
AU  - Terlizzi M
AD  - Department of Radiation Oncology, Gustave Roussy Institute, 114 Rue Edouard 
      Vaillant 94805 Villejuif, France.
FAU - Limkin, E
AU  - Limkin E
AD  - Department of Radiation Oncology, Gustave Roussy Institute, 114 Rue Edouard 
      Vaillant 94805 Villejuif, France.
FAU - Sellami, N
AU  - Sellami N
AD  - Department of Radiation Oncology, Gustave Roussy Institute, 114 Rue Edouard 
      Vaillant 94805 Villejuif, France.
FAU - Louvel, G
AU  - Louvel G
AD  - Department of Radiation Oncology, Gustave Roussy Institute, 114 Rue Edouard 
      Vaillant 94805 Villejuif, France.
FAU - Blanchard, P
AU  - Blanchard P
AD  - Department of Radiation Oncology, Gustave Roussy Institute, 114 Rue Edouard 
      Vaillant 94805 Villejuif, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230125
PL  - Ireland
TA  - Clin Transl Radiat Oncol
JT  - Clinical and translational radiation oncology
JID - 101713416
PMC - PMC9931895
OTO - NOTNLM
OT  - Pandemic
OT  - Radiosurgery
OT  - Single session
OT  - Stereotactic body radiation therapy
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2023/02/24 06:00
MHDA- 2023/02/24 06:01
PMCR- 2023/01/25
CRDT- 2023/02/23 09:27
PHST- 2022/07/25 00:00 [received]
PHST- 2023/01/15 00:00 [revised]
PHST- 2023/01/15 00:00 [accepted]
PHST- 2023/02/23 09:27 [entrez]
PHST- 2023/02/24 06:00 [pubmed]
PHST- 2023/02/24 06:01 [medline]
PHST- 2023/01/25 00:00 [pmc-release]
AID - S2405-6308(23)00009-5 [pii]
AID - 100584 [pii]
AID - 10.1016/j.ctro.2023.100584 [doi]
PST - epublish
SO  - Clin Transl Radiat Oncol. 2023 Jan 25;39:100584. doi: 10.1016/j.ctro.2023.100584. 
      eCollection 2023 Mar.